Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy:a comprehensive review  

作　　者：Mengyuan Li Minghuan Zhang Qian Ye Yunhua Liu Wenbin Qian 

机构地区：[1]Department of Hematology,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China [2]Hangzhou Rong-Gu Biotechnology Limited Company,Hangzhou 310056,China [3]Department of Pathology&Pathophysiology and Department of Surgical Oncology of the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310058,China

出　　处：《Cancer Biology & Medicine》2023年第9期646-661,共16页癌症生物学与医学（英文版）

基　　金：supported by the National Natural Science Foundation of China(Grant No.81830006);the Science Technology Department of Zhejiang Province(Grant No.2021C03117).

摘　　要：Oncolytic virotherapy has emerged as a promising treatment for human cancers owing to an ability to elicit curative effects via systemic administration.Tumor cells often create an unfavorable immunosuppressive microenvironment that degrade viral structures and impede viral replication;however,recent studies have established that viruses altered via genetic modifications can serve as effective oncolytic agents to combat hostile tumor environments.Specifically,oncolytic vaccinia virus(OVV)has gained popularity owing to its safety,potential for systemic delivery,and large gene insertion capacity.This review highlights current research on the use of engineered mutated viruses and gene-armed OVVs to reverse the tumor microenvironment and enhance antitumor activity in vitro and in vivo,and provides an overview of ongoing clinical trials and combination therapies.In addition,we discuss the potential benefits and drawbacks of OVV as a cancer therapy,and explore different perspectives in this field.

关 键 词：Oncolytic virotherapy oncolytic vaccinia virus engineered virus arming strategy 

分 类 号：R730.51[医药卫生—肿瘤]